Novo Nordisk To Invest $117 M in Diabetes-Drug Production Facilities
Novo Nordisk plans to invest DKK 800 million ($117 million) to upgrade and expand facilities at its production site in Kalundborg, Denmark, which currently manufacture a range of products for diabetes treatment.
The facilities will be rebuilt and expanded to allow for future production of diabetes-treatment products as well as future diabetes products. The projects are expected to be completed in 2022.
Established in 1969, the Kalundborg site covers a total area of 1.2 million square meters and employs more than 3,000 people. A range of biopharmaceutical products are also produced at the production site in Kalundborg.
Source: Novo Nordisk